Low-Dose Aspirin and Kidney Disease: What Are the Risks?

Low-dose aspirin poses a modest, usually reversible risk to kidney function in certain people, particularly older adults and those whose kidneys are already compromised. For most healthy individuals, the standard daily dose used for heart protection does not appear to cause lasting kidney damage. But the picture shifts considerably once kidney disease is already present: aspirin can still deliver meaningful cardiovascular benefits in that population, yet it also amplifies bleeding risk and may accelerate the rate at which kidney function declines. The balance between benefit and harm depends on the individual, and the research is less settled than you might expect.

How Low-Dose Aspirin Reaches the Kidneys

Aspirin works by blocking an enzyme involved in producing prostaglandins, which are hormone-like chemicals with wide-ranging effects throughout the body. In the kidneys, certain prostaglandins act as vasodilators: they widen the small blood vessels feeding the filtering units, helping to maintain blood flow and filtration when overall circulation drops. This compensatory mechanism kicks in during dehydration, heart failure, heavy blood-pressure medication use, or any other state where the effective blood volume falls.¹ When prostaglandin production is suppressed, those vessels can constrict, reducing blood flow to the kidney’s filters and lowering the rate at which waste is cleared from the blood.²

The crucial distinction with low-dose aspirin is that the dose matters enormously. At the typical heart-protective dose of around 75 to 150 mg per day, aspirin selectively shuts down thromboxane production in platelets (which is how it prevents clots) without significantly suppressing the prostaglandins that protect kidney blood flow. Research dating back to the 1980s showed that a daily low dose given over a month produced virtually complete inhibition of platelet clotting factors while leaving kidney prostaglandin synthesis intact, including the prostaglandin pathways triggered by diuretics.³ In healthy people with normal kidneys, then, the risk is minimal. The trouble starts when kidneys are already struggling or when other factors pile on.

Short-Term Effects in Older Adults

Several studies have specifically tracked what happens to kidney markers in elderly patients shortly after starting low-dose aspirin. The findings are consistent and somewhat sobering. In one study of 83 elderly patients, about 70% showed a measurable drop in creatinine clearance (a standard gauge of kidney filtering ability) after just two weeks on aspirin, with an average decline of roughly 19%. Blood markers of waste products like urea nitrogen and uric acid rose in parallel. When aspirin was stopped, these values improved, but about half of the patients still had not returned to their baseline kidney function three weeks later.⁴

A separate study of elderly patients found similar patterns: creatinine clearance dropped by about 19% and uric acid clearance by about 17% after two weeks, with roughly two-thirds of patients still showing some impairment after aspirin was withdrawn. Interestingly, patients who reacted most adversely tended to have better baseline kidney function but lower hemoglobin and albumin levels, hinting that their overall health context mattered as much as the drug itself.⁵ The researchers recommended monitoring kidney function even with low-dose aspirin in this age group.

These short-term dips sound alarming, but context helps. The largest randomized trial of aspirin in older adults, the ASPREE trial involving over 19,000 healthy people aged 65 and older, tracked kidney function for nearly five years. It found no difference in the annual rate of kidney function decline between those taking daily low-dose aspirin and those taking a placebo. The increase in urinary albumin (a marker of kidney damage) was also essentially the same between the two groups. The researchers concluded that fears about long-term kidney decline from low-dose aspirin in healthy older people “may not be justified.”⁶ The short-term dips in the smaller studies, then, may reflect a transient hemodynamic adjustment rather than actual kidney damage, at least in people without pre-existing kidney disease.

Does Long-Term Use Accelerate Kidney Disease?

For people who already have some degree of kidney disease, the evidence gets murkier. A large observational study found that long-term aspirin users had about a 30% higher odds of experiencing a steeper decline in kidney function compared to non-users. However, this faster decline did not translate into higher rates of end-stage kidney disease or death.⁷ That disconnect is worth sitting with: the kidneys appeared to lose function faster on paper, but the ultimate outcomes that matter most to patients were not significantly worse.

Findings from people with type 2 diabetes, who are at especially high risk for kidney problems, have been more reassuring. A Japanese cohort study following diabetic patients on low-dose aspirin found no increased incidence of albumin leaking into the urine, a hallmark of diabetic kidney damage, across years of follow-up.⁸ A randomized trial of 150 mg daily aspirin in type 2 diabetic patients who already had micro- or macroalbuminuria found that aspirin had no impact on albumin excretion or glomerular filtration rate, leading the researchers to conclude that aspirin does not interfere with the diagnosis or monitoring of kidney damage in this group.⁹

Part of the reason the evidence is so unsettled is that people with kidney disease have historically been excluded from or underrepresented in the major cardiovascular aspirin trials. Much of what we know comes from observational studies and secondary analyses rather than trials specifically designed to answer the kidney question.

Cardiovascular Benefits for People With Existing Kidney Disease

Kidney disease dramatically raises cardiovascular risk. People with moderate to advanced chronic kidney disease are far more likely to die of a heart attack or stroke than to progress to dialysis, which is why doctors often consider aspirin for these patients in the first place. The evidence that aspirin helps on the cardiovascular side in this population is surprisingly strong, though not unchallenged.

A meta-analysis of randomized controlled trials in patients with stage 3 to 5 chronic kidney disease found that aspirin reduced the risk of major cardiovascular events by about 24%, cardiovascular death by 40%, and all-cause death by 22%. The benefits were even more striking in patients with more advanced disease: among those with severely reduced kidney filtration, aspirin cut the risk of heart attack by roughly half and cardiovascular death by a similar margin.¹⁰

Not all the data agrees, however. A large observational study from South Korea found that aspirin users with CKD actually had a significantly higher incidence of atherosclerotic cardiovascular disease than non-users, even after statistical matching.¹¹ Observational studies like this are notoriously susceptible to confounding by indication, meaning that the people prescribed aspirin may have been sicker to begin with, which would inflate the apparent harm. The meta-analysis of randomized trials, which controls for this bias by design, carries more weight when the two conflict. Still, the disagreement underscores that prescribing aspirin in CKD is not a slam-dunk decision.

Why Bleeding Risk Is Amplified

The single biggest concern with aspirin in kidney disease is bleeding. Aspirin users with CKD had a major bleeding rate of about 6.7 per 1,000 person-years, compared with 4.7 per 1,000 person-years for non-users, a roughly 45% increase.¹² In the ASPREE trial, chronic kidney disease was identified as one of the independent risk factors that increased gastrointestinal bleeding among older aspirin users.¹³

The biological reason for this amplified risk runs deeper than just aspirin thinning the blood. Advanced kidney disease disrupts platelet function all on its own, a condition sometimes called uremic thrombopathy. Platelets in people with kidney failure already have trouble forming effective clots, and bleeding times are prolonged before aspirin even enters the picture.¹⁴ Adding aspirin on top of that pre-existing platelet dysfunction compounds the problem. Research has shown that aspirin prolongs bleeding time in uremic patients through a mechanism that goes beyond its usual effect on the clotting enzyme cyclooxygenase, meaning the bleeding risk in kidney disease is not just additive but qualitatively different.¹⁵

This is why the benefit-risk calculus of aspirin in advanced kidney disease is genuinely difficult. The cardiovascular benefits are large, but the bleeding risk is also large and biologically amplified. Clinicians have to weigh them for each patient, considering factors like the stage of kidney disease, history of gastrointestinal bleeding, and concurrent medications.

Drug Combinations That Raise the Stakes

If you have kidney disease, there is a good chance you are also taking blood pressure medications like ACE inhibitors, angiotensin receptor blockers, or diuretics. Each of these affects the kidney’s blood flow regulation in its own way. Taking an NSAID (the drug class to which aspirin belongs) alongside one of these medications does not appear to significantly raise the risk of acute kidney injury. But the combination of all three, sometimes called “triple therapy,” is a different story: a large nested case-control study found a 31% higher rate of acute kidney injury in people simultaneously taking a diuretic, an ACE inhibitor or ARB, and an NSAID.¹⁶

Low-dose aspirin is a weaker prostaglandin inhibitor than most other NSAIDs at the doses used for pain relief, so whether the triple-therapy risk applies equally to low-dose aspirin as to full-dose ibuprofen or naproxen is debated. But the underlying mechanism is the same: all three drug classes independently reduce the kidney’s ability to maintain blood flow under stress. When they converge, the kidney loses multiple backup systems at once. If you are on a blood pressure regimen that already includes both a diuretic and an ACE inhibitor or ARB, discussing aspirin with your doctor is especially important, and staying well-hydrated is a straightforward precaution that reduces the hemodynamic stress on the kidneys.

How Aspirin Compares to Clopidogrel

For patients with kidney disease who need antiplatelet therapy after a coronary stent or heart attack, the question sometimes shifts from “should I take aspirin” to “is there a gentler option?” Clopidogrel, the other common antiplatelet drug, works through a different pathway and does not inhibit prostaglandin production, which theoretically makes it kinder to the kidneys.

A small study of CKD patients with type 2 diabetes directly compared the two drugs. Over the study period, the clopidogrel group saw creatinine clearance improve by about 8%, while the aspirin group experienced a roughly 2.5% decline. The difference was statistically significant and led the researchers to suggest reconsidering aspirin’s status as the default antiplatelet agent in people with failing kidneys.¹⁷ A post-hoc analysis of the HOST-EXAM trial, which compared the two drugs after coronary stent placement, found that clopidogrel was associated with lower rates of adverse cardiovascular events than aspirin, and this advantage held regardless of whether the patient had CKD.¹⁸

Adding both aspirin and clopidogrel together (dual antiplatelet therapy) offers stronger clot prevention but substantially raises bleeding risk, which can in turn threaten the kidneys through volume loss and hemodynamic instability.¹⁹ For patients who need just one antiplatelet drug long-term, the evidence is leaning toward clopidogrel as a reasonable kidney-friendlier alternative, though it costs more and the head-to-head kidney data remains limited.

High-Dose Aspirin Is a Different Animal

Much of the historical anxiety about aspirin and kidneys traces back to the era of analgesic nephropathy, when people consumed large quantities of aspirin and acetaminophen, often in combination, for chronic pain. A case-control study published in the New England Journal of Medicine found that regular use of aspirin at analgesic doses was associated with a roughly 2.5-fold increase in the risk of chronic renal failure, with risk climbing as the cumulative lifetime dose rose. The association was present for aspirin used alone, though it was more consistently dose-dependent for acetaminophen.

That finding applies to doses far above what is used for cardiovascular prevention. Analgesic doses of aspirin typically run 600 mg to over 1,000 mg multiple times a day, while the cardioprotective dose is usually 75 to 150 mg once daily. At the lower dose, the selective inhibition of platelet thromboxane without wholesale prostaglandin suppression in the kidney is the key pharmacological difference. The distinction matters practically: if you’ve heard that “aspirin damages kidneys,” the warning was almost certainly about chronic high-dose use, not the baby aspirin your cardiologist prescribed.

Aspirin After a Kidney Transplant

Kidney transplant recipients occupy a unique niche in this discussion. Their new organ is vulnerable to blood clots forming in the transplant’s blood vessels, a complication called allograft thrombosis that can destroy the graft. A review of transplant studies found that aspirin reduced the risk of graft failure by about 43% and allograft thrombosis by nearly 90% compared to no treatment. It also lowered the risk of major cardiovascular events or death by about 28%. The drug did not, however, reduce rates of graft rejection or delayed graft function.²⁰

For transplant recipients, then, low-dose aspirin appears to be protective for the transplanted kidney rather than harmful to it, at least in the context of preventing vascular complications. Most transplant centers include aspirin as part of the standard post-transplant medication regimen for precisely this reason.

Aspirin in Pregnancy With Kidney Disease

Pregnant women with chronic kidney disease face an elevated risk of preeclampsia, a dangerous condition involving high blood pressure and organ damage. Low-dose aspirin is already widely recommended during pregnancy for preeclampsia prevention in high-risk women, and a study specifically examining women with stage 3 to 5 CKD found that aspirin therapy during pregnancy reduced the risk of severe preeclampsia from about 42% in the untreated group to about 14% in the treated group.²¹ Since preeclampsia itself can cause acute kidney injury and worsen underlying kidney disease, aspirin’s protective effect here is both a cardiovascular and a renal benefit, one of the clearest scenarios in which low-dose aspirin works in favor of the kidneys rather than against them.

Practical Monitoring if You Are Taking Low-Dose Aspirin

Given the uneven evidence, what should you actually do? If you have healthy kidneys and are taking low-dose aspirin for heart protection, routine kidney monitoring beyond your normal checkups is probably unnecessary, based on the ASPREE trial’s reassuring long-term data.⁶ If you are elderly or have pre-existing kidney impairment, periodic blood tests checking creatinine and potassium are a sensible precaution, especially in the first few weeks after starting aspirin.⁵

Staying hydrated sounds basic, but it genuinely matters. Aspirin’s kidney effects are most pronounced when the kidneys are already relying on prostaglandins to maintain blood flow, which happens during volume depletion. Avoiding dehydration removes the condition under which aspirin is most likely to cause trouble. Similarly, if you develop an illness involving vomiting, diarrhea, or reduced fluid intake, temporarily discussing aspirin with your doctor is reasonable. The drug is generally safe in steady-state conditions; it is the combination of aspirin plus physiological stress that tends to push vulnerable kidneys past their compensation threshold.